Yanxiao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yanxiao Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Dianwen Song
Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
1 shared publication Ennan Bin
National Institute of Biological Sciences, Beijing, China
1 shared publicationFeiran Gao
Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, International Campus, Zhejiang University, Haining, China
1 shared publicationHuimin Ning
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China; Department of Immunology, College of Basic Medicine, Qingdao University, Qingdao, Shandong 266071, China
1 shared publication- Jian Liu
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China
1 shared publication Jie Yuan
National Institute of Biological Sciences, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 26 September 2023
- Published by Springer Nature in Cell Discovery
- Vol. 9 (1) , 1-4
Aberrant differentiation of epithelial progenitors is accompanied by a hypoxic microenvironment in the paraquat-injured human lung
- 26 September 2023
- Published by Springer Nature in Cell Discovery
- Vol. 9 (1) , 1-4
Open AccessAberrant differentiation of epithelial progenitors is accompanied by a hypoxic microenvironment in the paraquat-injured human lung
- Open Access
- 11 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
SMAD4 is mutated in human lung cancer, but the underlying mechanism by which Smad4 loss-of-function (LOF) accelerates lung cancer metastasis is yet to be elucidated. Here, we generate a highly aggressive lung cancer mouse model bearing conditional Kras G12D , p53 fl/fl LOF and Smad4 fl/fl LOF mutations (SPK), showing a much higher incidence of tumor metastases than the Kras G12D , p53 fl/fl (PK) mice. Molecularly, PAK3 is identified as a downstream effector of Smad4, mediating metastatic signal transduction via the PAK3-JNK-Jun pathway. Upregulation of PAK3 by Smad4 LOF in SPK mice is achieved by attenuating Smad4-dependent transcription of miR-495 and miR-543. These microRNAs (miRNAs) directly bind to the PAK3 3′UTR for blockade of PAK3 production, ultimately regulating lung cancer metastasis. An inverse correlation between Smad4 and PAK3 pathway components is observed in human lung cancer. Our study highlights the Smad4-PAK3 regulation as a point of potential therapy in metastatic lung cancer.
- 11 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Open AccessLoss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
SMAD4 is mutated in human lung cancer, but the underlying mechanism by which Smad4 loss-of-function (LOF) accelerates lung cancer metastasis is yet to be elucidated. Here, we generate a highly aggressive lung cancer mouse model bearing conditional Kras G12D , p53 fl/fl LOF and Smad4 fl/fl LOF mutations (SPK), showing a much higher incidence of tumor metastases than the Kras G12D , p53 fl/fl (PK) mice. Molecularly, PAK3 is identified as a downstream effector of Smad4, mediating metastatic signal transduction via the PAK3-JNK-Jun pathway. Upregulation of PAK3 by Smad4 LOF in SPK mice is achieved by attenuating Smad4-dependent transcription of miR-495 and miR-543. These microRNAs (miRNAs) directly bind to the PAK3 3′UTR for blockade of PAK3 production, ultimately regulating lung cancer metastasis. An inverse correlation between Smad4 and PAK3 pathway components is observed in human lung cancer. Our study highlights the Smad4-PAK3 regulation as a point of potential therapy in metastatic lung cancer.
- Open Access
- 1 July 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (1) , 109327
Brain endothelial PTEN/AKT/NEDD4-2/MFSD2A axis regulates blood-brain barrier permeability
- 1 July 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (1) , 109327
Open AccessBrain endothelial PTEN/AKT/NEDD4-2/MFSD2A axis regulates blood-brain barrier permeability